Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

1,423 total articles

Freedom Capital Lifts C.H. Robinson Price Target to $206, Keeps Hold Rating After Resilient Q4 Results

Freedom Capital Lifts C.H. Robinson Price Target to $206, Keeps Hold Rating After Resilient Q4 Results

Freedom Capital Markets increased its price target on C.H. Robinson Worldwide to $206.00 from $155.00 and held a Hold rating after the company's fourth-quarter 2025 results, which the firm described as "resilient." The stock trades near its 52-week high following a substantial one-year gain, while multiple other brokerages have also adjusted their …

DA Davidson Sticks With Buy on Weyerhaeuser, Sees Upside to $31 Target

DA Davidson Sticks With Buy on Weyerhaeuser, Sees Upside to $31 Target

DA Davidson has maintained a Buy rating and a $31.00 price objective for Weyerhaeuser (NYSE: WY) after the timber and land company reported fourth-quarter 2025 results that slightly surpassed the firm's expectations. The broker raised its fiscal 2026 EBITDA projection by 4% and cited a stronger start to 2026 in the Land-Based Solutions segment as a…

TD Cowen Lifts Cullen/Frost Price Target to $160, Citing Strong Q4 Results and Balance Sheet Momentum

TD Cowen Lifts Cullen/Frost Price Target to $160, Citing Strong Q4 Results and Balance Sheet Momentum

TD Cowen raised its price target on Cullen/Frost Bankers to $160 from $154 while keeping its existing rating, noting the bank's stronger-than-expected fourth-quarter performance, ongoing balance sheet momentum and multi-year expansion strategy. Recent results and analyst revisions have supported a constructive outlook, even as the stock trades slig…

TD Cowen Keeps Hold on Beta Bionics at $17 After FDA Warning Letter; Financials and Q4 Revenue Provide Cushion

TD Cowen Keeps Hold on Beta Bionics at $17 After FDA Warning Letter; Financials and Q4 Revenue Provide Cushion

TD Cowen has reiterated a Hold rating and a $17.00 price target on Beta Bionics (BBNX) after the company received an FDA Warning Letter. The firm’s initial read suggests the letter does not impose burdensome remediation demands and will not block product sales or 510(k) submissions. Beta Bionics reported preliminary fourth-quarter 2025 revenue of a…

Benchmark Sticks with Buy on APA Corp, Sees $33 Target as Gas Marketing Strength Offsets Lowered EBITDA

Benchmark Sticks with Buy on APA Corp, Sees $33 Target as Gas Marketing Strength Offsets Lowered EBITDA

Benchmark has reaffirmed its Buy rating on APA Corp with a $33.00 price target, citing notable gas marketing gains that helped offset a downward revision to fourth-quarter EBITDA driven by mark-to-market commodity prices. APA has also reported significant curtailments domestically and foresees a temporary drop in Egyptian volumes due to a short pip…

BMO Reaffirms Outperform on Canadian National, Sets $158 Price Target as Company Reports Strong Q4 Results

BMO Reaffirms Outperform on Canadian National, Sets $158 Price Target as Company Reports Strong Q4 Results

BMO Capital has reiterated an Outperform rating on Canadian National Railway (CNI) with a $158.00 price target, reflecting confidence in the company’s margin profile and cash generation even as management warns of essentially flat freight volumes in 2026. Fourth-quarter adjusted results topped expectations on productivity gains, but analysts have t…